Biosynthesis of mycobacterial lipoarabinomannan: Role of a branching mannosyltransferase
Author contributions: D.K., S.B., V.D.V., and P.J.B. designed research; D.K., P.D., and M.J. performed research; D.K., B.G., D.C.C., and M.J. contributed new reagents/analytic tools; D.K., S.B., D.C., M.R.M., and D.C.C. analyzed data; and D.K., D.C.C., and P.J.B. wrote the paper.
Freely available online through the PNAS open access option.
Abstract
Lipoarabinomannan (LAM), one of the few known bacterial glycosylphosphoinositides (GPIs), occurs in various structural forms in Mycobacterium species. It has been implicated in key aspects of the physiology of Mycobacterium tuberculosis and the immunology and pathogenesis of tuberculosis. Yet, little is known of the biosynthesis of LAM. A bioinformatics approach identified putative integral membrane proteins, MSMEG4250 in Mycobacterium smegmatis and Rv2181 in M. tuberculosis, with 10 predicted transmembrane domains and a glycosyltransferase (GT) motif (DID), features that are common to eukaryotic mannosyltransferases (ManTs) of the GT-C superfamily that rely on polyprenyl-linked rather than nucleotide-linked sugar donors. Inactivation of M. smegmatis MSMEG4250 by allelic exchange resulted in altered growth and inability to synthesize lipomannan (LM) but accumulation of a previously uncharacterized, truncated LAM. MALDI-TOF/MS and NMR indicated a structure lower in molecular weight than the native molecule, a preponderance of 6-linked Manp residues, and the absence of 2,6-linked and terminal Manp. Complementation of the mutant with the corresponding ortholog of M. tuberculosis H37Rv restored normal LM/LAM synthesis. The data suggest that MSMEG4250 and Rv2181 are ManTs that are responsible for the addition of α(1→2) branches to the mannan core of LM/LAM and that arrest of this branching in the mutant deters formation of native LAM. The results allow for the presentation of a unique model of LM and LAM biosynthesis. The generation of mutants defective in the synthesis of LM/LAM will help define the role of these GPIs in the immunology and pathogenesis of mycobacterial infections and physiology of the organism.
Mycobacterial diseases, such as tuberculosis and leprosy, remain serious human public health problems. One critical feature that contributes to the particular pathogenicity and physiology of mycobacteria is the unique, highly hydrophobic and impermeable cell wall (1). Beyond the cytoplasmic membrane, the cell wall of Mycobacterium tuberculosis consists of a core of mycolic acids, arabinogalactan and peptidoglycan, providing the template for insertion of products such as the phthiocerol-containing lipids, the trehalose mycolates, phosphatidylinositol mannosides (PIMs), and their more glycosylated derivatives, lipomannan (LM) and lipoarabinomannan (LAM) (2), all of which contribute to the particular physiology and disease induction capacity of Mycobacterium species. LAM, in its various forms, including those with mannose (Man) “caps” (ManLAM), has been implicated in many of the key aspects of the pathogenesis of tuberculosis and leprosy, such as induction of phagocytosis, phagosomal alteration and inhibition of fusion with lysosomes, and induction of innate, humoral, and acquired T cell-mediated immunity (3, 4). However, all of these studies (often conflicting) were conducted with the isolated molecule. Mutants devoid of LAM are crucial to fully resolve its role in disease pathogenesis and bacterial physiology.
Although structurally well defined (5), the underlying enzymology and genetics of LAM biosynthesis are unknown. It has been believed, although not empirically demonstrated, that both LM and LAM have their origins in the PIMs, because all contain a phosphatidylinositol (PI) moiety (5, 6). The first step in PIM synthesis involves the transfer of a Manp residue to the 2 position of the myo-inositol ring of PI to form PIM1, catalyzed by PimA (7, 8). Biosynthesis proceeds by means of the sequential addition of Manp residues to PIM1 or its acylated counterpart (AcPIM1),§ catalyzed in part by PimB and PimC, to produce PIM species having from two (PIM2) to three (PIM3) Manp residues (9, 10). The Manp units at position 6 of the inositol of PIM3 are further elongated with Manp to generate higher PIMs (PIM4, PIM5, and PIM6) (11, 12). However, the mannosyltransferases (ManTs) involved in these biosynthetic steps have not been identified. PIM6 is likely a “dead-end” product, because it contains 2-linked Manp, a combination not found in the mannan core of LM/LAM (13); PIM4 is the likely precursor for the subsequent extension of the mannan chain, giving rise to “linear LM” (12), which is further mannosylated at the C-2 positions, resulting in mature, branched LM. LAM itself retains the PI end and mannan backbone of LM; the Araf (arabinofuranose) residues originate in decaprenyl-P-arabinofuranose (C50-P-Araf), and addition is partially catalyzed by EmbC (14).
The only well characterized glycosyltransferases (GTs) implicated in PIM/LM/LAM biosynthesis are the three initial ManTs, PimA, PimB, and PimC, and EmbC (8–10, 14). Apparently, the ManTs that use GDP-Man as sugar donors occur on the cytoplasmic face of the plasma membrane (15), whereas those responsible for further elongation, requiring C50-P-Man as the sugar donor, are likely located in the cytoplasmic membrane or extracytoplasmic space (12, 15, 16). The lumen-associated ManTs of the eukaryotic protein glycosylation pathway, relying on polyprenyl-linked sugar as donors and members of the GT-C superfamily of enzymes for glycosylation, are also invariably integral membrane proteins, sharing similar hydropathy plots and the presence of a conserved motif in an extracytoplasmic loop (17). Recent iterative BLAST searches of sequence databases advanced a list of 11 ORFs from the genome of M. tuberculosis with multiple transmembrane domains (17) (Table 2, which is published as supporting information on the PNAS web site). This development prompted us to examine these putative GTs through bioinformatics-informed mutagenesis as being responsible for the latter steps in LM/LAM biosynthesis.
Signal volumes were integrated and normalized to t-β-Araf, which was taken as the reference signal. Chemical shifts were measured in H2O at 500 MHz and 295 K. —, not detected.
Click here to view.Acknowledgments
We thank Christopher D. Rithner and Jian Zhang for NMR, Michael S. Scherman for electron microscopy, and Jessica Prenni for MALDI-TOF/MS analysis. This work was supported by National Institute of Allergy and Infectious Diseases/National Institutes of Health Grant AI-18357.
Abbreviations
| LM | lipomannan |
| LAM | lipoarabinomannan |
| PIM | phosphatidylinositol mannoside |
| GT | glycosyltransferase |
| ManT | mannosyltransferase |
| Araf | arabinofuranose |
| Man | mannose |
| PI | phosphatidylinositol |
| HSQC | heteronuclear single quantum correlation |
| Km | kanamycin. |
Footnotes
Conflict of interest statement: No conflicts declared.
This paper was submitted directly (Track II) to the PNAS office.
AcPIM or Ac2PIM is used to define the number of acyl groups, in addition to those attached to glycerol, esterified either to the 6-position of the Manp on carbon-2 of myo-inositol, or directly to the 3-position of myo-inositol.
References
- 1. Brennan PJ, Nikaido H. Annu Rev Biochem. 1995;64:29–63.[PubMed]
- 2. Crick DC, Brennan PJ, McNeil MR In: Tuberculosis. Rom WN, Garay SM, editors. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 115–134. [PubMed][Google Scholar]
- 3. Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, Puzo G. Microbes Infect. 2002;4:945–953.[PubMed]
- 4. Briken V, Porcelli SA, Besra GS, Kremer L. Mol Microbiol. 2004;53:391–403.[PubMed]
- 5. Chatterjee D, Hunter SW, McNeil M, Brennan PJ. J Biol Chem. 1992;267:6228–6233.[PubMed]
- 6. Hunter SW, Brennan PJ. J Biol Chem. 1990;265:9272–9279.[PubMed]
- 7. Hill DL, Ballou CE. J Biol Chem. 1966;241:895–902.[PubMed]
- 8. Kordulakova J, Gilleron M, Mikusova K, Puzo G, Brennan PJ, Gicquel B, Jackson M. J Biol Chem. 2002;277:31335–31344.[PubMed]
- 9. Schaeffer ML, Khoo KH, Besra GS, Chatterjee D, Brennan PJ, Belisle JT, Inamine JM. J Biol Chem. 1999;274:31625–31631.[PubMed]
- 10. Kremer L, Gurcha SS, Bifani P, Hitchen PG, Baulard A, Morris HR, Dell A, Brennan PJ, Besra GS. Biochem J. 2002;363:437–447.
- 11. Brennan P, Ballou CE. J Biol Chem. 1967;242:3046–3056.[PubMed]
- 12. Besra GS, Morehouse CB, Rittner CM, Waechter CJ, Brennan PJ. J Biol Chem. 1997;272:18460–18466.[PubMed]
- 13. Khoo KH, Dell A, Morris HR, Brennan PJ, Chatterjee D. Glycobiology. 1995;5:117–127.[PubMed]
- 14. Zhang N, Torrelles JB, McNeil MR, Escuyer VE, Khoo KH, Brennan PJ, Chatterjee D. Mol Microbiol. 2003;50:69–76.[PubMed]
- 15. Morita YS, Velasquez R, Taig E, Waller RF, Patterson JH, Tull D, Williams SJ, Billman-Jacobe H, McConville MJ. J Biol Chem. 2005;280:21645–21652.[PubMed]
- 16. Morita YS, Patterson JH, Billman-Jacobe H, McConville MJ. Biochem J. 2004;378:589–597.
- 17. Liu J, Mushegian A. Protein Sci. 2003;12:1418–1431.
- 18. Maeda Y, Watanabe R, Harris CL, Hong Y, Ohishi K, Kinoshita K, Kinoshita T. EMBO J. 2001;20:250–261.
- 19. Gibson KJ, Eggeling L, Maughan WN, Krumbach K, Gurcha SS, Nigou J, Puzo G, Sahm H, Besra GS. J Biol Chem. 2003;278:40842–40850.[PubMed]
- 20. Sassetti CM, Boyd DH, Rubin EJ. Mol Microbiol. 2003;48:77–84.[PubMed]
- 21. Kaur D, Lowary TL, Vissa VD, Crick DC, Brennan PJ. Microbiology. 2002;148:3049–3057.[PubMed]
- 22. Gilleron M, Himoudi N, Adam O, Constant P, Venisse A, Riviere M, Puzo G. J Biol Chem. 1997;272:117–124.[PubMed]
- 23. Shi L, Berg S, Lee A, Spencer JS, Zhang J, Vissa V, McNeil MR, Khoo KH, Chatterjee D. J Biol Chem. 2006;281:19512–19526.[PubMed]
- 24. Kovacevic S, Anderson D, Morita YS, Patterson J, Haites R, McMillan BN, Coppel R, McConville MJ, Billman-Jacobe H. J Biol Chem. 2006;281:9011–9017.[PubMed]
- 25. Yokoyama K, Ballou CE. J Biol Chem. 1989;264:21621–21628.[PubMed]
- 26. Khoo KH, Douglas E, Azadi P, Inamine JM, Besra GS, Mikusova K, Brennan PJ, Chatterjee D. J Biol Chem. 1996;271:28682–28690.[PubMed]
- 27. Raetz CR, Whitfield C. Annu Rev Biochem. 2002;71:635–700.
- 28. Gilleron M, Quesniaux VF, Puzo G. J Biol Chem. 2003;278:29880–29889.[PubMed]
- 29. Quesniaux VJ, Nicolle DM, Torres D, Kremer L, Guerardel Y, Nigou J, Puzo G, Erard F, Ryffel B. J Immunol. 2004;172:4425–4434.[PubMed]
- 30. Atlas RM In: Handbook of Microbial Media. 2nd Ed. Parks LC, editor. Boca Raton, FL: CRC; 1997. pp. 1225–1226. [PubMed][Google Scholar]
- 31. Escuyer VE, Lety MA, Torrelles JB, Khoo KH, Tang JB, Rithner CD, Frehel C, McNeil MR, Brennan PJ, Chatterjee D. J Biol Chem. 2001;276:48854–48862.[PubMed]
- 32. Jackson M, Crick DC, Brennan PJ. J Biol Chem. 2000;275:30092–30099.[PubMed]
- 33. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, et al Nature. 1991;351:456–460.[PubMed][Google Scholar]
- 34. Dobos KM, Khoo KH, Swiderek KM, Brennan PJ, Belisle JT. J Bacteriol. 1996;178:2498–2506.
- 35. Berg S, Starbuck J, Torrelles JB, Vissa VD, Crick DC, Chatterjee D, Brennan PJ. J Biol Chem. 2005;280:5651–5663.[PubMed]
- 36. Prinzis S, Chatterjee D, Brennan PJ. J Gen Microbiol. 1993;139:2649–2658.[PubMed]
- 37. Dell A, Reason AJ, Khoo KH, Panico M, McDowell RA, Morris HR. Methods Enzymol. 1994;230:108–132.[PubMed]
- 38. McNeil M, Chatterjee D, Hunter SW, Brennan PJ. Methods Enzymol. 1989;179:215–242.[PubMed]
- 39. Torrelles JB, Khoo KH, Sieling PA, Modlin RL, Zhang N, Marques AM, Treumann A, Rithner CD, Brennan PJ, Chatterjee D. J Biol Chem. 2004;279:41227–41239.[PubMed]





